Impact of human immunodeficiency virus infection on measures of cardiovascular disease in long-term nonprogressors

Infectious Diseases in Clinical Practice

Volumn 21, Issue 3, 2013, Pages 177-180

  Bonilla, Hector ^a   McShannic, Joseph ^b   Goldberg, Eric ^b   Chua, Daniel ^b   Conner, Ronald ^b   Fiorentino, Marc ^c   McComsey, Grace ^d  

^a MERCY HOSPITAL OF PITTSBURGH   (United States)

^b AKRON CITY HOSPITAL   (United States)

^c Clinicians in Infectious Diseases Inc   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; HIV; Long term nonprogressors

Indexed keywords

TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID INTIMA MEDIAL THICKENING; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE;

EID: 84879124799     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/IPC.0b013e31828262f3     Document Type: Article

References (19)

1. Schecter AD, Berman AB, Yi L, et al. HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci USA. 2001;98(18):10142-10147.
2. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109(13):1603-1608.
3. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23(9):1059-1067.
4. Ho JE, Hsue PY. Cardiovascular manifestations of HIV infection. Heart. 2009;95(14):1193-1202.
5. Eugenin EA, Morgello S, Klotman ME, et al. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol. 2008;172(4):1100-1111.
6. Mangili A, Polak JF, Quach LA, et al. Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis. 2011;214(2):468-473.
7. Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008;118(2):198-210.
8. Gaardbo JC, Hartling HJ, Gerstoft J, et al. Thirty years with HIV infection-nonprogression is still puzzling: lessons to be learned from controllers and long-term nonprogressors. AIDS Research and Treatment. 2012;2012:161584.
9. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the atherosclerosis risk in communities (ARIC) study, 1987-1993. Am J Epidemiol. 1997;146(6):483-494.
10. Martinez E, Larrousse M, Podzamczer D, et al, for the BICOO Study. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS. 2010;24(3):F1-F9
11. The CASCADE collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Concerted action on SeroConversion to AIDS and death in Europe. Lancet. 2000;355(9210):1158-1159.
12. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS. 2006;20(18):2275-2283.
13. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459-467.
14. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009;23(14):1841-1849.
15. Tungsiripat M, El-Bejjani D, Rizk N, et al. Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo. AIDS Res Hum Retroviruses. 2011;27(3):295-302.
16. Asztalos BF, Mujawar Z, Morrow MP, et al. Circulating nef induces dyslipidemia in simian immunodeficiency virusYinfected macaques by suppressing cholesterol efflux. J Infect Dis. 2010;202(4):614-623.
17. Hunt PW, Landay AL, Sinclair E, et al. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS ONE [Electronic Resource]. 2011;6(1):e15924.
18. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197(1):126-133.
19. DAD Study; Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723-1735.